Sign in
TNGX Stock Price, Chart, Stats & News
Tango Therapeutics, Inc.
Save
3.62B
Market cap
–
Current P/E
–
Forward P/E
TNGX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 97.34% |
Operating margin | -178.39% |
Pretax margin | -162.85% |
Net margin | -162.85% |
Effective tax rate | -0.00% |
ROA | -25.48% |
ROE | -50.30% |
D/E | 0.10x |
Interest coverage ratio | – |
TNGX valuation
P/E | – |
P/S | 35.87x |
P/B | 6.46x |
P/CF | -16.11x |
P/FCF | -15.99x |
P/OCF | -16.11x |
PEG | -5.01x |
EV multiple | -22.05x |
About
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions.
Similar securities
Based on sector and market capitalization
Report issue